DrugRisk Announces Addition of Januvia Cancer Resource Center

New York, NY (PRWEB) April 18, 2013

The prescription drug safety advocates at DrugRisk.com are announcing the launch of a new resource center for patients who have taken the diabetes drug Januvia, amid warnings that the drug may be related to pancreatic cancer and thyroid cancer.

The goal of DrugRisk is to improve patient safety by providing those taking prescription drugs with the latest warnings, recalls, studies and legal news. Patients can see if others are experiencing similar side effects and decide if they need legal advice.

Januvia is a once-a-day pill introduced in 2006 to help those with type-2 diabetes control blood sugar. It has become Mercks best-selling drug, with sales over $4 billion last year*.

However, DrugRisk has added a 2011 study from UCLA indicating the drug could increase the risk of pancreatic cancer by 272% and thyroid cancer by 148%**. The Journal for the American Medical Association also recently published findings showing Januvia could double the risk of pancreatitis, which is a risk factor for pancreatic cancer***.

Now, DrugRisk has learned that, with the number of patients filing a Januvia lawsuit alleging cancer growing, lawyers have requested that cases be consolidated to a special federal multi-district court in California****. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, United States Judicial Panel on Multidistrict Litigation).

Anyone affected by cancer after taking Januvia is encouraged to speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Januvia lawsuits.

For more information on the research, side effects and litigation news related to Januvia and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*bloomberg.com/news/2013-02-25/merck-bristol-diabetes-drugs-linked-to-pancreatitis-risk.html **ctsi.ucla.edu/education/files/publicview/training/docs/FDA-analysis.pdf ***archinte.jamanetwork.com/article.aspx?articleid=1656537 ****cdn.aboutlawsuits.com/wp-content/uploads/2013-04-05-Incretin-Mimetics-MDL.pdf

Read this article:
DrugRisk Announces Addition of Januvia Cancer Resource Center